10-Q: Shineco Inc. Reports Mixed Q1 2025 Results Amidst Restructuring and Capital Raising Efforts

Sentiment:

Quarterly Report 14 November 2024 4:05 PM

Shineco Inc. reports a net loss for the quarter ended September 30, 2024, while navigating business segment changes and raising capital through multiple offerings.

Capital raiseThe company raised approximately $7 million through a private placement of common stock.The company raised approximately $2 million through a public offering of common stock.The company raised approximately $8.2 million through a private placement of common stock, with some proceeds still expected.

Worse than expectedThe company reported a net loss of $2.6 million compared to a net income of $5.3 million in the same period last year.

Summary

Shineco Inc. reported a net loss of $2.6 million for the quarter ended September 30, 2024, compared to a net income of $5.3 million in the same period last year.
The company's revenue increased to $2.2 million, up from $1.6 million year-over-year, driven primarily by growth in agricultural product sales.
Operating expenses decreased to $2.7 million from $3.3 million year-over-year, due to reduced professional service fees and staff compensation.
The company completed a 1-for-24 reverse stock split effective November 12, 2024, and all share amounts have been retrospectively adjusted.
Shineco raised capital through multiple offerings, including a $7 million private placement, a $2 million public offering, and an $8.2 million private placement, with some proceeds still expected.
The company's short-term loans totaled $14.3 million and long-term loans totaled $1.8 million as of September 30, 2024.
The company's management has expressed substantial doubt about the company's ability to continue as a going concern for the next twelve months.

Sentiment

Score: 4

Explanation: The document presents a mixed picture with positive revenue growth but significant losses and going concern issues. The capital raising efforts are a positive sign, but the material weaknesses in internal controls and the management's doubt about the company's ability to continue as a going concern are major concerns.

Positives

Revenue increased by 32.11% year-over-year, driven by growth in agricultural product sales.
Gross profit increased significantly by 194.92% year-over-year.
Operating expenses decreased by 19.48% year-over-year, due to reduced professional service fees and staff compensation.
The company successfully raised capital through multiple offerings, totaling approximately $15.3 million.
The company has taken steps to address material weaknesses in internal controls.

Negatives

The company reported a net loss of $2.6 million for the quarter ended September 30, 2024.
The company has a negative working capital of $7.3 million as of September 30, 2024.
Management has expressed substantial doubt about the company's ability to continue as a going concern.
The company's disclosure controls and procedures were not effective at the reasonable assurance level as of the end of the period covered by this report due to material weaknesses.
The company experienced a decrease in sales of rapid diagnostic and other products.

Risks

The company's management has expressed substantial doubt about the company's ability to continue as a going concern.
The company has a negative working capital of $7.3 million.
The company's disclosure controls and procedures were not effective at the reasonable assurance level as of the end of the period covered by this report due to material weaknesses.
The company is subject to risks associated with operating in the PRC, including political, economic, and legal risks.
The company is dependent on continued financial support from its stockholders.
The company's ability to maintain its listing on the Nasdaq is subject to continued compliance with listing requirements.

Future Outlook

The company intends to use approximately 50% of the net proceeds from the Offering for mergers and acquisitions, approximately 25% for repaying outstanding convertible notes, and 25% for general corporate purposes. The company's management believes that the company's current access to loans, equity financing as well as financial support from its shareholders will be sufficient to meet its working capital needs for at least the next 12 months.

Management Comments

The company's management believes these factors raise substantial doubt about the company's ability to continue as a going concern for the next twelve months.
The company's management believes that the company's current access to loans, equity financing as well as financial support from its shareholders will be sufficient to meet its working capital needs for at least the next 12 months.

Industry Context

The company is operating in the healthcare, agriculture, and food industries, which are all subject to various market and regulatory risks. The company's performance is influenced by factors such as demand for its products, cost of raw materials, and competition. The company's expansion into new business segments such as rapid diagnostics and healthy meals reflects a broader trend of diversification in the healthcare and food industries.

Comparison to Industry Standards

The company's revenue growth of 32.11% year-over-year is a positive sign, but the net loss of $2.6 million indicates that the company is still struggling with profitability.
Compared to other companies in the healthcare and agriculture sectors, Shineco's financial performance is mixed. While some companies in these sectors are experiencing strong growth and profitability, others are facing challenges due to market conditions and competition.
The company's reliance on debt financing and equity offerings to fund its operations is a common practice for companies in the growth phase, but it also increases the company's financial risk.
The company's management's expression of doubt about the company's ability to continue as a going concern is a significant concern and is not typical for companies in the healthcare and agriculture sectors.
The company's material weaknesses in internal controls are also a concern and need to be addressed to ensure the reliability of financial reporting.

Legal Proceedings

The company was involved in a lawsuit with Ms. Guiqin Li, which was settled in January 2023.
The company was involved in a lawsuit with Lei Zhang and Yan Li, which was settled in December 2023.

Related Party Transactions

The company has made temporary advances to certain stockholders and senior management of the Company and to other entities that are either owned by family members of those stockholders or to other entities that the Company has investments in.
The company had related party payables of $2.3 million in relation to the operations of Biowin and Wintus.
The company made sales of $391,808 to its related party, Chongqing Fuling District Renyi Zhilu Silk Industry Co., Ltd.
The company's related parties provide a guarantee for the company's bank loans.
The company entered into a two-year lease agreement for the lease of office space from a related party company.

Stakeholder Impact

Shareholders are impacted by the net loss and the company's going concern issues.
Employees are impacted by the company's cost control measures and potential restructuring.
Customers are impacted by the company's product offerings and service quality.
Suppliers are impacted by the company's ability to pay for goods and services.
Creditors are impacted by the company's debt levels and ability to repay loans.

Next Steps

The company intends to use approximately 50% of the net proceeds from the Offering for mergers and acquisitions, approximately 25% for repaying outstanding convertible notes, and 25% for general corporate purposes.
The company is committed to monitoring the effectiveness of the measures taken to address the material weaknesses in internal controls and making any changes that are necessary and appropriate.

Key Dates

Date	Description
2003-12-15	Tenet-Jove was incorporated.
2006-07-14	Tenet-Jove was granted the status of a wholly foreign-owned entity by Chinese authorities.
2016-12-10	Tenet-Jove entered into a purchase agreement with Tianjin Tajite.
2017-09-30	Tenet-Jove established Xinjiang Shineco Taihe Agriculture Technology Ltd. and Xinjiang Tianyi Runze Bioengineering Co., Ltd.
2019-03-13	Tenet-Jove established Beijing Tenjove Newhemp Biotechnology Co., Ltd.
2020-07-23	Shanghai Jiaying International Trade Co., Ltd. was established.
2021-01-07	Inner Mongolia Shineco Zhonghemp Biotechnology Co., Ltd. was established.
2021-06-08	Tenet-Jove entered into a Restructuring Agreement.
2021-06-16	The Company issued an unsecured convertible promissory note.
2021-07-16	The Company issued two unsecured convertible promissory notes.
2021-08-19	The Company issued an unsecured convertible promissory note.
2021-12-07	The Company established Shineco Life Science Research Co., Ltd.
2022-04-13	The Company established Shineco Life Science Group Hong Kong Co., Limited.
2022-04-24	The Company entered into a Share Transfer Agreement with Shineco Life.
2022-09-07	The Company signed an extension amendment with the Investor to extend the maturity date of the Note.
2022-10-21	The Company entered into a stock purchase agreement with the Seller and Biowin.
2022-12-30	Shineco Life closed the acquisition of 51% of the issued equity interests of Changzhou Biowin Pharmaceutical Co., Ltd.
2023-05-16	Fuzhou Meida Health Management Co., Ltd and Shinkang Technology (Jiangsu) Co., Ltd were established.
2023-05-23	Life Science established Beijing Shineco Chongshi Information Consulting Co., Ltd.
2023-05-29	Shineco Life entered into a stock purchase agreement with Dream Partner Limited, Chongqing Wintus Group, and certain shareholders of Dream Partner.
2023-06-15	The Company signed a second extension amendment with the Investor to extend the maturity date of the Note.
2023-07-31	The management determined that July 31, 2023 was the acquisition date of Wintus.
2023-08-30	The Board of Directors of the Company approved the issuance of shares of common stock pursuant to the Companys 2023 Equity Incentive Plan.
2023-09-19	The Company closed the Acquisition of Wintus.
2023-12-22	The Company entered into a securities purchase agreement with certain non-US investors.
2024-02-16	The 1-for-10 reverse stock split became effective.
2024-06-11	The Company signed a third extension amendment with the Investor to extend the maturity date of the Note.
2024-06-18	The Board of Directors of the Company approved the issuance of shares of common stock pursuant to the Companys 2024 Equity Incentive Plan.
2024-06-20	The Company entered into a securities purchase agreement with certain non-U.S. investors.
2024-07-11	The Company entered into an Underwriting Agreement with EF Hutton LLC.
2024-07-15	The Offering closed.
2024-08-22	The Company entered into a securities purchase agreement with 22 purchasers.
2024-09-10	The closing of the transaction contemplated by the SPA took place.
2024-09-30	End of the reporting period.
2024-10-21	The Companys stockholders approved a 1-for-24 reverse stock split.
2024-11-12	The 1-for-24 reverse stock split became effective.
2024-11-14	Date of report.

Keywords

Shineco Inc., financial results, quarterly report, reverse stock split, capital raise, going concern, internal controls, agricultural products, rapid diagnostics, convertible notes, China operations

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.